Article

Comorbidity patterns vary with rheumatologic disease

Separate patterns of comorbidity are identified in patients who have fibromyalgia syndrome (FMS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and noninflammatory rheumatic disorders (NIRD). The patterns include the type of comorbid variables reported and their associations with age and disease duration.

Separate patterns of comorbidity are identified in patients who have fibromyalgia syndrome (FMS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and noninflammatory rheumatic disorders (NIRD). The patterns include the type of comorbid variables reported and their associations with age and disease duration.

Wolfe and associates examined the prevalence of lifetime and current comorbidities and their impact on quality of life in 1316 patients with SLE, 2733 with FMS, 13,722 with RA, and 3623 with NIRD. Participants were enrolled in a longitudinal study of rheumatologic disease outcomes.

Comorbidity was most common in persons with FMS; there was a pattern of increase in depression, mental illness, and addiction and a second pattern that involved asthma, allergies, GI problems, neurological issues, and genitourinary diseases. Persons with SLE had hypertension; depression; cataracts; fractures; and cardiovascular, cerebrovascular, neurological, pulmonary, and gallbladder diseases. The most common conditions to accompany RA were hypertension, endocrine problems, psychiatric problems, GI distress, depression, cataracts, and diabetes mellitus. The comorbidity index increased with age in persons with RA or NIRD but remained steady between ages 35 and 84 years for persons with FMS or SLE.

The authors noted that not all coexistent conditions are comorbid.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.